Abstract 1265: Tissue is alive: Preserving phosphoproteins and tissue morphology in clinical trial samples
Claudius Mueller(Mayo Clinic), Virginia Espina(George Mason University), Frankie A. Holmes(Texas Oncology), Rosa I. Gallagher(George Mason University), Lorenzo Colarossi, Antonella Chiechi(Cedars-Sinai Medical Center), Lance A. Liotta(George Mason University), Yasir M. Nagarwala, Amy VanMeter(George Mason University), Kirsten H. Edmiston(Inova Health System)
Cited by 0
Related Papers
Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial
|The Lancet Oncology|2017|594
Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies
|Cancer Cell|2022|335
Blood–brain barrier permeable nano immunoconjugates induce local immune responses for glioma therapy
|Nature Communications|2019|297
Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI‐TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer
|Disease Markers|2001|287
TIMP-2 reduces proteolytic opening of blood-brain barrier by type IV collagenase
|Brain Research|1992|282